A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With
Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab
(DeLLphi-305)